禾元生物：公司120吨奥福民重组人白蛋白生产线正在按第二季度完成设备调试的计划全力推进

Core Viewpoint - The company is actively working on the installation and debugging of its new production capacity, specifically the 120-ton Afumin® recombinant human albumin production line, with plans to complete this by the second quarter [2]. Group 1: Production Capacity - The company is focused on completing the equipment debugging for the new production line by the second quarter [2]. - The release of the new production capacity is contingent upon compliance with national regulations and approval from the drug regulatory authority [2].